Brokerage firm Leerink Swann Downgrades its rating on Syneron Medical Ltd.(NASDAQ:ELOS). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by Leerink Swann was issued on Aug 5, 2016.
Syneron Medical Ltd. (ELOS) shares turned negative on Wednesdays trading session with the shares closing down -0.07 points or -1.00% at a volume of 50,382. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $7.06. The peak price level was also seen at $7.06 while the days lowest was $6.89. Finally the shares closed at $6.92. The 52-week high of the shares is $10.37 while the 52-week low is $6.1. According to the latest information available, the market cap of the company is $244 M.
Syneron Medical Ltd.(ELOS) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $74.72M. Analysts had an estimated revenue of $75.72M. Earnings per share were $0.09. Analysts had estimated an EPS of $0.06.
Syneron Medical Ltd. is engaged in manufacture research development marketing and sales of advanced equipment for the aesthetic medical industry and systems for dermatologists plastic surgeons and other qualified practitioners. The Company designs develops and markets aesthetic medical products based on its various technologies including Electro-Optical Synergy (ELOS) technology to provide aesthetic medical treatments. The Company’s products targets an array of non-invasive aesthetic medical procedures including hair removal wrinkle reduction rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions acne treatment treatment of leg veins treatment for the temporary reduction in the appearance of cellulite and thigh circumference ablation and resurfacing of the skin laser-assisted lipolysis and topical skin brightening products.